Seeking Alpha

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the ...
Seeking Alpha

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher Prostate ...
Business Wire

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers ...
Nasdaq

New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced that data published in the journal Cancer show the ability of a novel gene expression signature to classify ...
Morningstar

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...
Insider Monkey

Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO

Veracyte, Inc. (NASDAQ:VCYT) announced that eight new studies featuring its Decipher Prostate and Decipher Bladder genomic classifiers will be presented at the ASCO 2025 annual meeting in Chicago, ...
Morningstar

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

The findings were derived using Veracyte’s Decipher GRID (Genomic Resource for Intelligent Discovery) research tool. The study is among nine Decipher-focused abstracts—including six selected for ...
Nasdaq

New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data ...
Yahoo Finance

Veracyte Inc. (12V.SG) Q3 FY2025 earnings call transcript

Earnings call Veracyte delivered Q3 2025 revenue of $131.9M, up 14% YoY, with testing revenue up 17% and a record 30.1% adjusted EBITDA margin. Strong Decipher and Afirma growth led to raised 2025 ...
Business Wire

Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting new data on the genomic underpinnings of prostate and bladder cancers will ...
01Net

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology SOUTH SAN ...
Yahoo Finance

Veracyte, Inc. (VCYT) Q3 FY2025 earnings call transcript

Earnings call Veracyte delivered Q3 2025 revenue of $131.9M, up 14% YoY, with testing revenue up 17% and a record 30.1% adjusted EBITDA margin. Strong Decipher and Afirma growth led to raised 2025 ...